338 related articles for article (PubMed ID: 29576386)
21. The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.
Gay F; Cavallo F; Palumbo A
Drugs; 2015 Mar; 75(4):367-75. PubMed ID: 25764394
[TBL] [Abstract][Full Text] [Related]
22. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
23. Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy.
Krishnan A; Vij R; Keller J; Dhakal B; Hari P
Am Soc Clin Oncol Educ Book; 2016; 35():210-21. PubMed ID: 27249701
[TBL] [Abstract][Full Text] [Related]
24. Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020.
Devarakonda S; Cottini F; Bumma N; Khan A; Sharma N; Chaudhry M; Benson D; Rosko A; Efebera Y
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33187184
[TBL] [Abstract][Full Text] [Related]
25. All transplantation-eligible patients with myeloma should receive ASCT in first response.
Moreau P; Attal M
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):250-4. PubMed ID: 25696863
[TBL] [Abstract][Full Text] [Related]
26. Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020.
Du J; Zhuang J
Chronic Dis Transl Med; 2021 Dec; 7(4):220-226. PubMed ID: 34786541
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of newly diagnosed multiple myeloma in transplant-eligible patients].
Sakaida E
Rinsho Ketsueki; 2020; 61(9):1306-1316. PubMed ID: 33162530
[TBL] [Abstract][Full Text] [Related]
28. [The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)].
; ;
Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):341-346. PubMed ID: 32370461
[TBL] [Abstract][Full Text] [Related]
29. [The most recent developments in diagnosis and treatment of multiple myeloma].
Jurczyszyn A; Olszewska-Szopa M
Przegl Lek; 2017; 74(1):30-6. PubMed ID: 29693999
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
31. What is the role of autologous transplant for lymphoma in the current era?
Stiff P
Hematology Am Soc Hematol Educ Program; 2015; 2015():74-81. PubMed ID: 26637704
[TBL] [Abstract][Full Text] [Related]
32. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.
Gandolfi S; Vekstein C; Laubach JP; O'Brien A; Masone K; Munshi NC; Anderson KC; Richardson PG
Clin Adv Hematol Oncol; 2018 Aug; 16(8):564-574. PubMed ID: 30148829
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
34. Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients.
Gentile M; Vigna E; Recchia AG; Morabito L; Martino M; Morabito F
Expert Opin Pharmacother; 2014 Jul; 15(10):1315-20. PubMed ID: 24819321
[TBL] [Abstract][Full Text] [Related]
35. [Treatment strategy in untreated transplant-eligible multiple myeloma patients].
Sunami K
Rinsho Ketsueki; 2016; 57(10):2064-2073. PubMed ID: 27795516
[TBL] [Abstract][Full Text] [Related]
36. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
37. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.
Moreau P; Giralt SA
Leuk Res; 2012 Nov; 36 Suppl 1():S13-8. PubMed ID: 23176719
[TBL] [Abstract][Full Text] [Related]
38. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
39. Role of autologous bone marrow transplant in multiple myeloma.
Blanes M; de la Rubia J
Curr Opin Oncol; 2012 Nov; 24(6):733-41. PubMed ID: 23079784
[TBL] [Abstract][Full Text] [Related]
40. Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
Merz M; Raab MS; Goldschmidt H; Hillengass J
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2521-2526. PubMed ID: 28653099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
